GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » COGS-to-Revenue

Ocean Biomedical (Ocean Biomedical) COGS-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical COGS-to-Revenue?

Ocean Biomedical's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

Ocean Biomedical's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ocean Biomedical's Gross Margin % for the three months ended in Sep. 2023 was N/A%.


Ocean Biomedical COGS-to-Revenue Historical Data

The historical data trend for Ocean Biomedical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical COGS-to-Revenue Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
- - - -

Ocean Biomedical Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocean Biomedical COGS-to-Revenue Calculation

Ocean Biomedical's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Ocean Biomedical's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocean Biomedical  (NAS:OCEA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ocean Biomedical's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Ocean Biomedical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocean Biomedical (Ocean Biomedical) Business Description

Traded in Other Exchanges
Address
55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
Executives
Robert J Sweeney officer: Chief Accounting Officer 20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey director 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens director C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria officer: Chief Strategy Officer 19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra officer: Chief Financial Officer 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria director C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo director 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc 10 percent owner OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr officer: EVP, Innov./Acad. P'ships Head OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng director, officer: Chief Executive Officer OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc 10 percent owner 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526

Ocean Biomedical (Ocean Biomedical) Headlines

From GuruFocus

Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.

By sperokesalga sperokesalga 05-31-2023